TR
3SBio Inc.
TRSBF · OTC
$2.15 +0.00% (+$0.00)
Market Cap ¥35.9B
P/E Ratio 4.35x
Div. Yield 1.48%
ROE 38.21%
Bulios Fair Price
$3.12
45.1% upside
Current Price
$2.15
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TRSBF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Strong
7/9Valuation
97 /100
Cheap EV/EBITDA 2.43x
P/S 2.08x
P/B 1.32x
Growth
100 /100
Growing Rev. growth 35.96%
FCF growth 96.31%
Book val. growth 28.06%
Profitability
100 /100
Strong Net margin 47.93%
Op. margin 59.66%
FCF margin 52.95%
Quality
91 /100
Excellent ROE 38.21%
ROA 22.78%
Asset turnover 0.48x
Debt
100 /100
Low Current ratio 5.13x
Int. coverage 138.22x
Net debt/EBITDA -0.90x
Stability
31 /100
Unstable Rev. volatility 42.76%
EPS volatility 166.61%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TRSBF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jing Lou
Employees
6,109
Headquarters
Shenyang
Upcoming events
30 MAR
Earnings
Upcoming earnings report